Events / Exhibitions
Seminar Life Science
[Free Webinar] drug2drugs AI-AAM - our new AI and chemical-simulation based drug discovery service (May 24, 2024)
Outline
- Date
- Friday, May 24th, 2024
- Time
- 7:00 a.m. PDT / 10:00 a.m. EDT / 15:00 p.m. BST / 16:00 p.m. CEST
- Registration
- Click HERE
Don't miss out on the opportunity to learn more and see how your organization can benefit from drug2drugs AI-AAM®.
Summary of the webinar
Title: Accelerate drug discovery with AI-AAM®: Using AI to discover drugs and improve existing compounds
Are you interested in how AI is revolutionizing drug discovery? Join us for a free webinar hosted by Drug Discovery World, where Dr. Shino Ohira, Ph.D., research expert at the FUJIFILM Analysis Technology Center, will be sharing about our proprietary AI-Amino Acid Mapping (AI-AAM®) technology. We will discuss how AI-AAM® can accelerate drug discovery in a precise and cost-effective manner.
This is a great opportunity for anyone in the pharma & biotech industry looking to stay ahead of the curve about the latest technology in drug discovery. You'll gain insights into how AI-AAM® can streamline the drug discovery process and enhance lead optimization with scaffold hopping/substituent modification, generating a list of ~100 candidate compounds with improved toxicity, synthesizability, and thermal stability, from only the structural information of the bioactive region of the compound.
In this webinar you'll learn
- What is the AI-AAM® method and how exactly does it work?
- What evidence is there showing that the AI-AAM® method is effective in identifying drug candidates?
- How can drug2drugs help me in my efforts in drug discovery?
Who should attend
- Companies developing drugs or antibodies (pharma companies, biotech companies, agrochemical companies, etc.)
- Researchers/academia in the field of drug discovery
What is drug2drugs®?
drug2drugs® is a service to provide you multiple active compounds with different scaffolds from only the structural information of one active compound without knowing the target protein, so that we can increase the overall success rate of clinical drug development.
An active compound is a compound that has the ability to bind to its target protein. Having multiple active compounds with diverse scaffolds is important for improving the success rate in drug development to avoid various problems, such as low solubility, high toxicity or low permeability.
Fujifilm has developed AI-AAM® (AI-Amino-Acid Mapping), a new scaffold transformation method based on AI and chemical simulation, with the aim of increasing the number of active compounds with various scaffolds from one active compound. Scaffold transformation using AI-AAM® requires only the structural information of an active compound, not the information of the target protein.
We start drug2drugs®, a service that increases the number of active compounds from active small molecules or peptides by scaffold transformation of AI-AAM®.